# FOXO4-DRI

Canonical source: https://retacompare.com/encyclopedia/foxo4-dri

Disrupts the FOXO4-p53 interaction in senescent cells, freeing p53 to trigger intrinsic apoptosis selectively in senescent cells (senolytic).

Reference facts

Also known asFOXO4-D-Retro-Inverso, ProxofimTM (research)CategoryMitochondrial & Cellular LongevityMechanism of actionDisrupts the FOXO4-p53 interaction in senescent cells, freeing p53 to trigger intrinsic apoptosis selectively in senescent cells (senolytic).TargetsFOXO4-p53 complexIndications under research or approvedResearch — senescent cell clearance, age-related diseaseRegulatory status (reference entry)Preclinical / research onlyHalf-lifeHours (DRI form resists proteolysis)SequenceLTLRKEPASEIAQSILEAYSQNGWANRRSGGKRPPPRRRQRRKKRGSequence notesD-retro-inverso (DRI) peptide derived from the FOXO4 / p53 interaction interface, fused to a HIV-Tat-derived cell-penetrating sequence.Molecular weight (Da)5305First reported2017OriginDesigned by de Keizer lab; published in Cell 2017.
    Primary References

Baar et al., Cell 2017 (FOXO4-DRI senolytic)


    Explore research articles about FOXO4-DRI


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Baar et al., Cell 2017 (FOXO4-DRI senolytic): https://pubmed.ncbi.nlm.nih.gov/28340339/